Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | TMEM97 | Q5BJF2 | 6/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.57 |
| ▸ | HTR1A | P08908 | 1/20 | 0.57 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.57 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.57 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.57 |
| ▸ | DRD1 | P21728 | 1/20 | 0.57 |
| ▸ | HRH2 | P25021 | 1/20 | 0.57 |
| ▸ | HTR1B | P28222 | 1/20 | 0.57 |
| ▸ | HTR2A | P28223 | 1/20 | 0.57 |
| ▸ | HTR2C | P28335 | 1/20 | 0.57 |
| ▸ | HTR1E | P28566 | 1/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.57 |
| ▸ | HRH1 | P35367 | 1/20 | 0.57 |
| ▸ | HTR2B | P41595 | 1/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3934434 | 0.99 | MEN1 (0.59) | MEN1KMT2ANPSR1TMEM97SIGMAR1 | |
| SCHEMBL9727540 | 0.90 | NPSR1 (0.68) | MEN1KMT2ANPSR1TMEM97SIGMAR1 | |
| SCHEMBL6132364 | 0.89 | GAA (0.69) | MEN1KMT2ANPSR1TMEM97SIGMAR1 | |
| SCHEMBL19211095 | 0.88 | MEN1 (0.56) | MEN1KMT2ANPSR1TMEM97SIGMAR1 | |
| Hydrochloric Acid SCHEMBL19211077 | 0.87 | MEN1 (0.55) | MEN1KMT2ANPSR1TMEM97SIGMAR1 | |
| SCHEMBL27208439 | 0.87 | TMEM97 (0.58) | MEN1KMT2ANPSR1TMEM97SIGMAR1 | |
| SCHEMBL975238 | 0.86 | NPSR1 (0.60) | MEN1KMT2ANPSR1TMEM97SIGMAR1 | |
| SCHEMBL19950156 | 0.86 | MEN1 (0.60) | MEN1KMT2ANPSR1TMEM97SIGMAR1 | |
| SCHEMBL12814257 | 0.86 | MEN1 (0.60) | MEN1KMT2ANPSR1TMEM97SIGMAR1 | |
| SCHEMBL8642538 | 0.85 | MEN1 (0.59) | MEN1KMT2ANPSR1TMEM97SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109702-A1 | NOVEL GSPT PROTEIN DEGRADER AND APPLICATION THEREOF | GENOSCO INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-12521440-B2 | Degradation of bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use | BEONE MEDICINES I GMBH (CH) | 2026-01-13 | — | — | US | disclosed |
| US-20250205345-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEIGENE SWITZERLAND GMBH (CH) | 2025-06-26 | — | — | US | disclosed |
| EP-4562013-A1 | SUBSTITUTED IMIDAZOPYRAZINE COMPOUNDS AS IRAK3 BINDERS | CELGENE CORPORATION (US) | 2025-06-04 | — | — | EP | disclosed |
| CN-119630668-A | Substituted imidazopyrazines as IRAK3 binding agents | 细胞基因公司 | 2025-03-14 | — | — | CN | disclosed |
| US-20240366769-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEIGENE SWITZERLAND GMBH (CH) | 2024-11-07 | — | — | US | disclosed |
| CN-118475571-A | Degradation of Bruton Tyrosine Kinase (BTK) by conjugation of BTK inhibitors to E3 ligase ligands and methods of use | 百济神州有限公司 | 2024-08-09 | — | — | CN | disclosed |
| WO-2024102970-A1 | COMPOUNDS FOR MODULATING SYK ACTIVITY AND E3 UBIQUITIN LIGASE ACTIVITY | Kronos Bio, Inc. (US) | 2024-05-16 | — | — | WO | disclosed |
| WO-2024026260-A1 | SUBSTITUTED IMIDAZOPYRAZINE COMPOUNDS AS IRAK3 BINDERS | CELGENE CORPORATION (US) | 2024-02-01 | — | — | WO | disclosed |
| EP-4253412-A2 | INHIBITION OF CYTOKINE-INDUCED SH2 PROTEIN IN NK CELLS | The Walter and Eliza Hall Institute of Medical Research (AU) | 2023-10-04 | — | — | EP | disclosed |
| US-7569561-B2 | 2,4-diaminopyrimidines useful for treating cell proliferation diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-08-04 | — | — | US | disclosed |
| US-7569561-B2 | 2,4-diaminopyrimidines useful for treating cell proliferation diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-08-04 | — | — | US | disclosed |
| EP-2041132-A2 | NEW COMPOUNDS | Boehringer Ingelheim International GmbH (DE) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008148868-A1 | PIPERIDINE/PIPERAZINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-12-11 | — | — | WO | disclosed |
| WO-2008148851-A1 | PIPERIDINE/PIPERAZINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-12-11 | — | — | WO | disclosed |
| WO-2008003766-A2 | 4-HETER0CYCL0ALKYLPYRI(MI)DINES, PROCESS FOR THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-01-10 | — | — | WO | disclosed |
| US-20070207999-A1 | New Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-09-06 | — | — | US | disclosed |
| US-20070207999-A1 | New Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-09-06 | — | — | US | disclosed |
| US-20070207999-A1 | New Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-09-06 | — | — | US | disclosed |
| WO-2007096351-A1 | 2,4-DIAMINOPYRIMIDINE DERIVATIVES FOR THE TREATMENT AND/OR PREVENTION OF CANCER, INFECTIONS, INFLAMMATORY AND AUTOIMMUNE DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240366769-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BTK, CBL, LYN | MEN1 3386/4885KMT2A 1210/4885NPSR1 4431/4885 |
| US-20260109702-A1 | NOVEL GSPT PROTEIN DEGRADER AND APPLICATION THEREOF | CRBN, PSMB3, PSMB1 | MEN1 1730/4885KMT2A 2696/4885NPSR1 1786/4885 |
| US-20070207999-A1 | New Compounds | CCNA1, MKI67, CCNT1 | MEN1 74/4885KMT2A 4243/4885NPSR1 453/4885 |
| US-20250205345-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BTK, CBL, LYN | MEN1 3386/4885KMT2A 1210/4885NPSR1 4431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.